aflibercept

Overview

Aflibercept is a therapeutic biologic used primarily as an anti-angiogenic agent. It functions as a soluble decoy receptor that binds vascular endothelial growth factor (VEGF) ligands, thereby reducing VEGF-mediated signaling involved in pathological neovascularization and vascular permeability. In ophthalmology, this mechanism underlies its use in retinal diseases such as neovascular age-related macular degeneration (nAMD) and diabetic macular oedema, where excessive VEGF activity contributes to abnormal blood vessel growth and leakage.

Beyond eye disease, aflibercept has also been studied in oncology as part of anti-angiogenic treatment strategies, including combination regimens for metastatic colorectal cancer. Recent research continues to evaluate its comparative effectiveness, pharmacokinetics, biosimilar performance, and delivery systems designed to extend dosing intervals while maintaining efficacy and safety.

Role in Recent Research

Recent publications have focused on aflibercept in several clinically relevant contexts, especially ophthalmology.

One real-world study compared faricimab and aflibercept as second-line therapies for neovascular age-related macular degeneration. The stated aim was to assess comparative effectiveness in routine practice, reflecting ongoing interest in how aflibercept performs relative to newer anti-VEGF therapy options such as faricimab.

Another study examined the biological effects of aflibercept and faricimab on VEGF-A165-induced vascular permeability using human-derived endothelial cells. This head-to-head in vitro comparison reported that aflibercept and faricimab equipotently restored endothelial barrier function, supporting the idea that both agents can counteract VEGF-driven barrier disruption.

A pharmacometric analysis of intravitreal aflibercept drug products evaluated population pharmacokinetics across formulations. The study reported that a high-dose product delivering 8 mg aflibercept every 12 or 16 weeks after initial monthly dosing produced visual gains non-inferior to the 2 mg formulation given every 8 weeks after initial monthly dosing, with comparable safety and fewer injections over 96 weeks. This work is relevant to efforts to reduce treatment burden in chronic retinal disease.

Biosimilar development was also represented in a 20-week extension study of MYL-1701P, a biosimilar aflibercept product, in diabetic macular oedema. The extension followed participants from a 52-week global phase III trial and was designed to assess safety, efficacy, and immunogenicity. This indicates continued evaluation of biosimilar anti-VEGF options as alternatives to reference aflibercept.

Drug-delivery innovation was another theme. A materials science study described a visible light photo-cross-linked thermogel as a single-component hybrid supramolecular-covalent hydrogel for sustained drug release. In that system, aflibercept was used as the antivascular endothelial growth factor biologic released from an in situ cross-linked depot, with release prolonged for more than 3 months. The authors framed this as a potential improvement over monthly injection regimens used for diseases such as nAMD.

Aflibercept also appeared in an oncology trial in older adults or frail elderly patients with metastatic colorectal cancer. In that randomized phase 2 study, aflibercept and 5-FU were compared with FOLFOX as first-line treatment. The publication situates aflibercept within fluoropyrimidine-based and angiogenesis-inhibitor-based treatment strategies for frail patients, although the provided context does not include detailed outcome data.

Finally, a nationwide Japanese database analysis of intravitreal injections and anti-VEGF agent use from 2017 to 2022 found that aflibercept remained the predominant anti-VEGF agent. The study also noted diversification after the introduction of brolucizumab and faricimab, indicating that aflibercept continues to occupy a central position in real-world retinal therapy practice.